VipStockReports

Stocks to Keep Your Eyes On: UniPixel Inc (NASDAQ:UNXL), Sunesis Pharmaceuticals, Inc, Merrimack Pharmaceuticals Inc, dELiA*S, Inc

 
Repost This

Middletown, DE -- (SBWIRE) -- 10/02/2013 -- VipStockReports.com screens the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way. Today our focus is on: UniPixel Inc (NASDAQ:UNXL), Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), dELiA*s, Inc. (NASDAQ:DLIA).

UniPixel Inc (NASDAQ:UNXL), ended with a volume of 1.60 million shares versus the average volume of the stock 1.13 million shares. The stock grew6.24 % and ended at $18.82. The market capitalization of the stock remained 226.55 million. The beta of the stock was -0.81.

Will UNXL Continue To Move Higher? Find Out Here

Uni-Pixel, Inc. (Uni-Pixel) is a production-stage company delivering its Performance Engineered Film (PEF) to the display, touch screen and flexible electronics markets. The Company has developed thin film high volume roll to roll or continuous flow manufacturing process.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS), traded 1.53 million shares in the last business day while the average volume of the stock remained 268,589 shares. The 52 week range of the stock remained $3.60 - $6.85. The stock showed a positive movement of 1.21% to end at $5.02. The market capitalization of the stock remained 259.51 billion.

For How Long SNSS’s Gloss will Attract Investors? Find Out Here

Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK), its volume was 948,138 shares as compared to the average volume of 1.50 shares. The stock boosted2.90% in its last trading session and reached a price of $3.90. The stock, on average, trades 1.50 shares each day.

Will MACK Continue To Move Higher? Find Out Here

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer.

dELiA*s, Inc. (NASDAQ:DLIA) showed a volume of 187,572 shares by the end of last trade whereas the average volume of the stock remained 330,550 shares. The 52 week range of the stock remained $0.63 - $1.83 and the day range was $1.15 - $1.24. The stock opened the session at $1.20 but then moved to $1.20. At that price, the stock showed a negative performance of -0.83%.

Will DLIA Get Buyers Even After The Recent Rally? Find Out Here

dELiA*s, Inc. is a retail company comprised of two lifestyle brands primarily targeting teenage girls and young women. The Company generates revenue by selling predominantly to teenage consumers through direct mail catalogs, Websites and retail stores.

About VipStockReports.com:
We screen the markets looking for Hot Emerging Micro-cap and Small cap stocks that look to Run High. Once we find the 'Next Hot Penny Stock' with Monster Upside Potential we immediately Email it to you in our detailed VIP Report so you can Beat Rest of the Crowd!!

Our team STRONGLY believes the penny stock market can powerfully reward average traders, and we are here to lead the way.

Disclaimer:
VipstockReports.com newsletters and website: The disclaimer is to be read entirely and fully understood before using our website, or joining our newsletter email list. Never invest into a stock discussed on this website or the Vipstockalerts.com newsletter unless you can afford to lose your entire investment. Please consult with a certified financial advisor before making any investment decisions.

VipStockReports.com and any affiliates and information providers make no implied or express warranties on the information provided. Please verify quotes with your financial advisor before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. As with any stock, the featured companies profiled on the VipstockReports.com web site and/or newsletter involve a high degree of volatility and risk, and all investors should know that they may lose a portion of or all of their investment if they decide to purchase any stocks.

Read Full Disclaimer at: http://www.vipstockreports.com/disclaimer/